Research programme: bacteriophage therapeutics - Ferring Pharmaceuticals/Institut Pasteur

Drug Profile

Research programme: bacteriophage therapeutics - Ferring Pharmaceuticals/Institut Pasteur

Latest Information Update: 02 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ferring Pharmaceuticals; Institute Pasteur
  • Developer Ferring Pharmaceuticals; Institute Pasteur; Intralytix
  • Class Bacteriophages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Bacterial infections; Inflammatory bowel diseases

Most Recent Events

  • 02 Feb 2017 Ferring Pharmaceuticals and Intralytix agree to co-develop and commercialise bacteriophage therapeutics in USA for Bacterial infections
  • 09 Jan 2017 Intralytix has patent protection for use of bacteriophage technology to regulate the microbiome in USA
  • 09 Jan 2017 Early research in Bacterial infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top